Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 123, Issue 12, 2016, Pages 1900-1907

  Eke, A C ^a   Saccone, G ^b   Berghella, V ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Depression; drug; malformation; prematurity; preterm birth

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT;

DRUG USE; HIGH RISK PREGNANCY; HUMAN; INCIDENCE; OUTCOME ASSESSMENT; PREGNANCY; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PUERPERAL DEPRESSION; REVIEW; RISK; RISK ASSESSMENT; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; CONTROLLED CLINICAL TRIAL (TOPIC); DEPRESSION; EVIDENCE BASED MEDICINE; FEMALE; META ANALYSIS; PREGNANCY COMPLICATIONS; PREMATURE BIRTH; UNITED STATES;

ANTIDEPRESSIVE AGENTS; CONTROLLED CLINICAL TRIALS AS TOPIC; DEPRESSION; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INCIDENCE; PREGNANCY; PREGNANCY COMPLICATIONS; PREMATURE BIRTH; SEROTONIN UPTAKE INHIBITORS; UNITED STATES;

EID: 84971619912     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.14144     Document Type: Review

References (29)

1. Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 2005;106:1071–83.
2. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birthweight, and intrauterine growth restriction. Arch Gen Psychiatry 2010;67:1012–24.
3. Wadhwa PD, Entringer S, Buss C, Lu MC. The contribution of maternal stress to preterm birth: issues and considerations. Clin Perinatol 2011;38:351–84.
4. Ornoy A, Koren G. Selective serotonin reuptake inhibitors in human pregnancy: on the way to resolving the controversy. Semin Fetal Neonatal Med 2014;19:188–94.
5. Huybrechts KF, Bateman BT, Palmsten K, Desai RJ, Patorno E, Gopalakrishnan C, et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA 2015;213:2142–51.
6. Myles N, Newall H, Ward H, Large M. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust N Z J Psychiatry 2013;47:1002–12.
7. Nifkar S, Rahimi R, Hendoiee N, Abdollahi M. Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: a systematic review and updated meta-analysis. Daru 2012;20:75.
8. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0 (update March 2011). The Cochrane Collaboration, 2011. [www.cochrane-handbook.org] Accessed 21 October 2015.
9. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS). Development and validation of a new instrument. ANZ J Surg 2003;73:712–6.
10. Peters J, Mengersen K. Selective reporting of adjusted estimates in observational epidemiology studies: reasons and implications for meta-analyses. Eval Health Prof 2008;31:370–89.
11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–12.
12. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.
13. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004;158:312–6.
14. Kallen B, Reis M. Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy. J Clin Psychopharmacol 2012;32:608–14.
15. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129–32.
16. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006;63:898–906.
17. Hayes RM, Wu P, Shelton RC, Cooper WO, Dupont WD, Mitchel E, et al. Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies. Am J Obstet Gynecol 2012;207:49.e1–9.
18. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010–5.
19. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009;163:949–54.
20. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002;159:2055–61.
21. Huang H, Coleman S, Bridge JA, Yonkers K, Katon W. A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birthweight. Gen Hosp Psychiatry 2014;36:13–8.
22. Huybrechts KF, Sanghani RS, Avorn J, Urato AC. Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis. PLoS ONE 2014;26:e92778.
23. Kitamura T, Shima S, Sugarawa M, Toda MA. Psychological and social correlates of the onset of affective disorders among pregnant women. Psychol Med 1993;23:967–75.
24. Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009;31:403–13.
25. Spinelli M, Endicott J. Controlled clinical trial of interpersonal psychotherapy versus parenting education program for depressed pregnant women. Am J Psychiatry 2003;160:555–62.
26. Headley J, Northstone K, Simmons H, Golding J; ALSPAC Study team. Medication use during pregnancy: data from the Avon Logitudinal Study of Parents and Children. Eur J Clin Pharmacol 2004;60:355–661.
27. Cooper WO, Pont ME, Ray WA. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007;196:544e1.
28. Berkowitz GS, Papiernik E. Epidemiology of preterm birth. Epidemiol Rev 1993;15:414–43.
29. Vorhees CV, Acuff-Smith KD, Schilling MA, Fisher JE, Moran MS, Buelke-Sam J. A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol 1994;23:194–205.